[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.220.120. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1987

Inflammatory Breast CarcinomaEffective Multimodal Approach

Author Affiliations

From the Departments of Medicine (Drs Burton, Cox, Olsen, and Hart), Surgery (Drs Leight, Iglehart, and Seigler), and Radiation Therapy (Dr Prosnitz), Duke University Medical Center, Durham, NC. Dr Burton is now with the Department of Medicine, Louisiana State University Medical Center, Shreveport.

Arch Surg. 1987;122(11):1329-1332. doi:10.1001/archsurg.1987.01400230117020
Abstract

• Twenty-two patients with inflammatory breast carcinoma received preoperative chemotherapy consisting of weekly administration of cyclophosphamide, doxorubicin hydrochloride, fluorouracil, and vincristine sulfate for six weeks. Postoperative therapy consisted of 22 weeks of biweekly administration of these drugs. Regional radiotherapeutic consolidation followed chemotherapy. Nineteen patients completed therapy. Twelve of these patients remain disease free (median, 15 months; range, four to 32 months). Median disease-free survival for all 22 patients is 13 months or more (range, zero to 32 months). Median overall survival is 18 months or more (range, one to 33 months). This regimen compares favorably with prolonged adjuvant and maintenance chemotherapy for inflammatory breast carcinoma.

(Arch Surg 1987;122:1329-1332)

×